François Godart1, Ali Houeijeh2, Morgan Recher2, Charles Francart2, Anne-Sophie Polge3, Marjorie Richardson3, Marie-Andrée Cajot4, Alain Duhamel5. 1. Université Lille Nord de France, Département de Cardiologie Infantile et Congénitale, Centre Hospitalier Régional et Universitaire de Lille, Faculté de Médecine Lille 2, Lille, France. Electronic address: francois.godart@chru-lille.fr. 2. Université Lille Nord de France, Département de Cardiologie Infantile et Congénitale, Centre Hospitalier Régional et Universitaire de Lille, Faculté de Médecine Lille 2, Lille, France. 3. Université Lille Nord de France, Département d'Échocardiographie, Département de Physiologie, Centre Hospitalier Régional et Universitaire de Lille, Faculté de Médecine Lille 2, Lille, France. 4. Université Lille Nord de France, Département d'Échocardiographie, Département d'Anesthésie et de Réanimation Cardiaque, Centre Hospitalier Régional et Universitaire de Lille, Faculté de Médecine Lille 2, Lille, France. 5. Université Lille Nord de France, Département de Biostatistiques, EA 2694; Centre Hospitalier Régional et Universitaire de Lille, Faculté de Médecine Lille 2, Lille, France.
Abstract
BACKGROUND: Single-centre experience in transcatheter closure of atrial septal defect (ASD) using the Figulla(®) ASD Occluder (FSO; Occlutech GmbH, Jena, Germany) and the Amplatzer(®) Septal Occluder (ASO; Saint-Jude Medical, Zaventem, Belgium) has been reported. AIM: To perform a retrospective comparison of the two occluders. METHODS: From September 2009 to December 2012, 131 consecutive patients underwent percutaneous ASD occlusion: One hundred with the ASO device; 31 with the FSO device. RESULTS: There were no significant differences between the two groups regarding patient characteristics, stretched diameter, age and device size. In the ASO group, implantation succeeded in all but two patients because of deficient rim. Another patient had device embolization in the aorta retrieved percutaneously. During follow-up, 86 patients had no residual shunt and nine patients had a residual shunt (small in seven; moderate in two). Two other patients had persistent interatrial small shunt caused by an adjacent ASD close to the device. In the FSO group, implantation succeeded in all but two patients: one because of deficient posterior rim; and one because of complete atrioventricular block that resolved after device extraction. During follow-up, no shunt was observed in all but one patient. At late follow-up (up to 36months), full occlusion was observed in 88 (88.0%) patients in the ASO group and 28 (90.3%) patients in the FSO group (with no significant difference between groups). CONCLUSION: Transcatheter closure of ASD with the FSO is feasible and safe. FSO results compare favorably with ASO results. However, additional long-term studies that include more patients are mandatory.
BACKGROUND: Single-centre experience in transcatheter closure of atrial septal defect (ASD) using the Figulla(®) ASD Occluder (FSO; Occlutech GmbH, Jena, Germany) and the Amplatzer(®) Septal Occluder (ASO; Saint-Jude Medical, Zaventem, Belgium) has been reported. AIM: To perform a retrospective comparison of the two occluders. METHODS: From September 2009 to December 2012, 131 consecutive patients underwent percutaneous ASD occlusion: One hundred with the ASO device; 31 with the FSO device. RESULTS: There were no significant differences between the two groups regarding patient characteristics, stretched diameter, age and device size. In the ASO group, implantation succeeded in all but two patients because of deficient rim. Another patient had device embolization in the aorta retrieved percutaneously. During follow-up, 86 patients had no residual shunt and nine patients had a residual shunt (small in seven; moderate in two). Two other patients had persistent interatrial small shunt caused by an adjacent ASD close to the device. In the FSO group, implantation succeeded in all but two patients: one because of deficient posterior rim; and one because of complete atrioventricular block that resolved after device extraction. During follow-up, no shunt was observed in all but one patient. At late follow-up (up to 36months), full occlusion was observed in 88 (88.0%) patients in the ASO group and 28 (90.3%) patients in the FSO group (with no significant difference between groups). CONCLUSION: Transcatheter closure of ASD with the FSO is feasible and safe. FSO results compare favorably with ASO results. However, additional long-term studies that include more patients are mandatory.
Authors: Alvaro Aparisi; Roman J Arnold; Hipólito Gutiérrez; Ana Revilla; Ana Serrador; Benigno Ramos; Tania Rodriguez-Gabella; Alberto Campo; Carlos Baladrón; Itziar Gómez; Manuel Carrasco-Moraleja; José A San Roman; Ignacio J Amat-Santos Journal: Cardiol J Date: 2020-04-24 Impact factor: 2.737
Authors: Isabelle Boon; Katrien Vertongen; Bernard P Paelinck; Laurent Demulier; An Van Berendoncks; Catherine De Maeyer; Fabienne Marchau; Joseph Panzer; Kristof Vandekerckhove; Daniel De Wolf Journal: Pediatr Cardiol Date: 2017-09-27 Impact factor: 1.655
Authors: Raymond N Haddad; Diala Khraiche; Damien Bonnet; Mathilde Meot; Sophie Malekzadeh-Milani Journal: Front Pediatr Date: 2021-03-11 Impact factor: 3.418
Authors: Roel J R Snijder; Laura E Renes; Martin J Swaans; Maarten Jan Suttorp; Jurrien M Ten Berg; Martijn C Post Journal: J Interv Cardiol Date: 2020-09-07 Impact factor: 2.279